Rakesh Govindji

Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.

Duke University spin-out, Deep Blue Medical Advances has developed a novel hernia mesh to address the unacceptably high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost. Our surgeon-invented T-Line® Hernia Mesh with integral suture-like extensions is designed to eliminate a key point of failure for conventional mesh fixation - the mesh, suture, tissue interface - and to provide superior anchor strength. In addition, several additional products are in development, including an anchor clip for even faster, easier implantation; a biosynthetic version of the T-Line Hernia Mesh; and a coated composite version of the T-Line Mesh. Deep Blue products enhance hernia surgery with a potentially significant impact on the $1.1B global hernia device market. Due to its simple yet revolutionary design, the T-Line® Hernia Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure.

At Calon Cardio, we are pioneering the future of left ventricular assist devices (LVADs), the emerging gold standard in heart failure treatment. Our expert team is developing an innovative pump that is smaller, more efficient, and optimized for better blood handling, setting a new standard in patient care compared to existing solutions. We are driven by a mission to enhance the quality of life for LVAD patients, and part of this vision includes integrating cutting-edge wireless charging technology. Our goal is to redefine what is possible in advanced heart failure management and ensure that patients have access to the best solutions available.

We are working towards a transplant of insulin producing cells combined with nanosensors for diabetes that is so safe and effective we would put it in our own bodies and the bodies of people we love. We believe our ability to create more robust and controlled insulin producing cell transplants that can be monitored in vivo over time will revolutionize the current clinical landscape for diabetes and cell replacement therapy.

The scope of experience of Polaris’s executive team spans nine decades & several fields, including military service, medicine, & federal research & development. These experiences have allowed the team to cultivate timely knowledge of pandemic-era mental health needs, & develop deeply unique qualifications to address these needs. The team has garnered numerous awards, ranks, titles, & accomplishments, ranging from captain to engineer, Purple Heart recipient to medical doctor, virologist & immunologist, 9/11 responder to Iraq War veteran, & PhD to Homeland Security Public Health Officer amid the threats of SARS & anthrax. In 2017, inspired by their work at the Defense & Veterans Brain Injury Center & the US Department of Veterans Affairs, a veteran & a scientist coalesced their visions seeded in service around the urgent need for 21st-century innovation in behavioral healthcare. Drawing upon decades of experience in biomedical technology, public health, & molecular biology, they founded a company to take aim at the mental health crisis that results in 22 veteran suicides each day. Partnering with the Illumina Accelerator & scientists from Mount Sinai & the Max Planck Institute of Psychiatry, the team developed the first-to-market, patented genomic biomarker assay to identify PTSD risk in 2018. As a veteran-owned business, our roots remain in our founding mission to improve the lives of US military service members & veterans living with behavioral health conditions, such as post-traumatic stress disorder (PTSD). In 2020, global public health events & an evolving behavioral health landscape revealed that the number of people standing to benefit from advances in diagnostics & treatment is broadening by the day. Guided by a calling to serve, we expanded our mission to encompass: - Veterans & active-duty US military service members, - First responders, frontline workers, & individuals in high-risk occupations, & - Trauma-exposed communities at large.

ATTENTION: If you are contacted by somebody claiming to be from Knopp Biosciences regarding an open position (examples have included remote data entry positions), and that they saw your profile on LinkedIn, it is not legitimate. Someone is using our information without our knowledge or consent. Please block that person and discontinue contact with them. We are not currently recruiting for any positions. Apologies for any confusion caused by these scam attempts.

Betr is a socially sustainable health platform that utilizes food as medicine and gut health to restore healing from the inside. By restoring the gut-brain connection the body can naturally prevent and reverse chronic disease. A global movement of individuals, employers, health plans, and families are turning the dial from survive to thrive. Join the movement at betrhealth.com.

At Arrivo, we strive to set a new standard in drug development that starts with the selection of drug candidates and runs throughout clinical development. Our approach and decision-making has delivered a history of excellent returns and product successes that makes us the trusted partner for industry and investors.

Neuronex is a development stage pharmaceutical company focused on drugs that treat Central Nervous System (CNS) diseases and disorders. The company aims to combine clinical expertise with a thorough knowledge of the drug development process in a nimble, entrepreneurial environment, to achieve rapid success in obtaining approvals for our products.

Aerial BioPharma LLC is a pharmaceuticals company based out of Aerial Center Executive Park, 9001 Aerial Center Parkway, Suite 110, Morrisville, NC, United States.

A network for entrepreneurs building in stealth. Submit your information here so investors can find you: harmonic.ai/get-discovered

Areteia Therapeutics is a new biotechnology company committed to putting asthma patients in better control of their disease—and back in control of their lives—with the first potential oral drug for eosinophilic asthma.

Duke University spin-out, Deep Blue Medical Advances has developed a novel hernia mesh to address the unacceptably high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost. Our surgeon-invented T-Line® Hernia Mesh with integral suture-like extensions is designed to eliminate a key point of failure for conventional mesh fixation - the mesh, suture, tissue interface - and to provide superior anchor strength. In addition, several additional products are in development, including an anchor clip for even faster, easier implantation; a biosynthetic version of the T-Line Hernia Mesh; and a coated composite version of the T-Line Mesh. Deep Blue products enhance hernia surgery with a potentially significant impact on the $1.1B global hernia device market. Due to its simple yet revolutionary design, the T-Line® Hernia Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure.

At Calon Cardio, we are pioneering the future of left ventricular assist devices (LVADs), the emerging gold standard in heart failure treatment. Our expert team is developing an innovative pump that is smaller, more efficient, and optimized for better blood handling, setting a new standard in patient care compared to existing solutions. We are driven by a mission to enhance the quality of life for LVAD patients, and part of this vision includes integrating cutting-edge wireless charging technology. Our goal is to redefine what is possible in advanced heart failure management and ensure that patients have access to the best solutions available.

We are working towards a transplant of insulin producing cells combined with nanosensors for diabetes that is so safe and effective we would put it in our own bodies and the bodies of people we love. We believe our ability to create more robust and controlled insulin producing cell transplants that can be monitored in vivo over time will revolutionize the current clinical landscape for diabetes and cell replacement therapy.